Veterinary Molecular Diagnostics Market (2026-2036)

The growth of this market is mainly driven by the rising incidence of transboundary and zoonotic animal diseases such as African swine fever, highly pathogenic avian influenza, and bluetongue, which require rapid and sensitive PCR testing for surveillance and outbreak control; the growing companion animal population and rising spending on pet healthcare; the expansion of reference laboratory molecular testing panels for companion animals; and the increasing adoption of genomic testing in livestock breeding and production. In addition, the shift toward point-of-care molecular testing in veterinary clinics, the growing use of sequencing for pathogen characterization and genomic surveillance, the One Health approach to zoonotic disease monitoring, and the expansion of veterinary laboratory infrastructure in emerging economies are further supporting the growth of this market.

The Veterinary Molecular Diagnostics Market, also referred to as the animal molecular diagnostics market, veterinary PCR testing market, or veterinary nucleic acid testing market, comprises the kits and reagents, instruments, and software used to detect and analyze the DNA and RNA of pathogens and animals for the diagnosis, surveillance, and management of animal diseases and for genetic testing. The market includes real-time PCR, digital PCR, and conventional PCR assays for viral, bacterial, parasitic, and fungal pathogens; multiplex syndromic panels for respiratory, gastrointestinal, vector-borne, and reproductive diseases; nucleic acid extraction kits and automated extraction systems; PCR thermal cyclers and point-of-care molecular analyzers; DNA sequencing for pathogen characterization, genomic surveillance, and genotyping; microarrays for genotyping and genomic selection; and laboratory information and data analysis software. The market ecosystem extends from manufacturers of molecular assays, instruments, and sequencing platforms to veterinary reference laboratories, national and state veterinary diagnostic laboratories, veterinary hospitals and clinics, livestock producers and breeding organizations, and research institutes.

Molecular diagnostics has become an essential part of veterinary medicine because of its sensitivity, specificity, and speed. PCR can detect very small amounts of pathogen genetic material, often before clinical signs appear or antibodies develop, and can distinguish closely related pathogens and strains. These capabilities make molecular testing the method of choice for confirming outbreaks of notifiable diseases, screening animals before movement and trade, monitoring herds and flocks, and diagnosing infectious diseases in companion animals. Multiplex PCR panels now allow veterinarians to test for many pathogens in a single sample, supporting faster and more targeted treatment.

Transboundary and zoonotic animal diseases are a major source of demand. According to the World Organisation for Animal Health (WOAH), 76 countries and territories reported African swine fever (ASF) between January 2022 and June 2026, with 14,951 outbreaks in domestic pigs, 2.74 million animal losses, and 34,388 outbreaks in wild boar, and in July 2026 Finland reported its first-ever occurrence of the disease in wild boar. Because there is no widely available vaccine for ASF in most countries, control depends on early detection, culling, and movement restrictions, all of which rely on PCR testing by national and regional laboratories. Highly pathogenic avian influenza (HPAI) H5N1 has spread widely in wild birds and poultry and, since 2024, in dairy cattle in the U.S. In the U.S., the U.S. Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS) continues to implement the National Milk Testing Strategy with State veterinarians for H5N1 surveillance of the national milk supply and dairy herds, alongside the Federal Order of April 2024 requiring testing of lactating dairy cattle before interstate movement. In the U.K., the Department for Environment, Food and Rural Affairs (Defra) confirmed 270 cases of bluetongue virus serotype 3 (BTV-3) on farm holdings in England and Wales by August 7, 2026, less than a month after the first case of the 2026-2027 season was confirmed on July 10, 2026, following 348 cases in Great Britain in the 2025-2026 season. These outbreaks create sustained demand for PCR kits, extraction reagents, and high-throughput laboratory instruments.

The companion animal segment is the other major driver of the market. Pet ownership and spending on veterinary care have grown strongly, and veterinarians increasingly use molecular testing to diagnose respiratory, gastrointestinal, vector-borne, and other infectious diseases in dogs and cats. In the second quarter of 2026, IDEXX Laboratories, Inc. reported revenue of USD 1,217 million, up 10% year over year, with Companion Animal Group (CAG) Diagnostics recurring revenue of USD 974.7 million, up 11%, reference laboratory diagnostic and consulting services revenue of USD 406.7 million, up 11%, and Livestock, Poultry and Dairy revenue of USD 35.2 million, up 11%, and the company raised its full-year 2026 revenue guidance to USD 4,700-4,745 million. Reference laboratories offer extensive PCR panels, and the development of point-of-care molecular analyzers is beginning to bring PCR testing into the veterinary clinic.

Genetics is an increasingly important application. Livestock producers use DNA genotyping for genomic selection, parentage verification, and the identification of genetic defects and traits, and companion animal owners and breeders use DNA tests for genetic disease screening and breed identification. In March 2026, Neogen Corporation announced the sale of its global genomics business, operating under the GeneSeek brand and including the Igenity and GGP portfolios, to Zoetis Inc. for USD 160 million; the business generated approximately USD 90 million in sales in fiscal 2025. This transaction reflects the strategic importance of animal genomics and the convergence of diagnostics and genetics in animal health.

The market includes leading animal health and diagnostics companies such as IDEXX Laboratories, Antech Diagnostics (part of Mars, Incorporated), and Zoetis, life science companies such as Thermo Fisher Scientific, QIAGEN, and Bio-Rad Laboratories, and specialized veterinary molecular diagnostics providers such as Indical Bioscience, Innovative Diagnostics, and Neogen. These companies compete on the breadth of assay menus, regulatory approvals and validations, sensitivity and specificity, laboratory throughput and automation, turnaround time, and the integration of testing with practice management and data systems.

At the same time, the market faces challenges, including the high cost of molecular testing relative to rapid antigen and antibody tests, limited laboratory infrastructure and skilled personnel in many developing countries, the need for regulatory approval or validation of veterinary assays in different countries, and the interpretation of PCR results, as the detection of nucleic acid does not always indicate active infection. Price sensitivity in livestock production and fluctuations in demand linked to outbreak cycles also affect the market. As a result, companies that combine broad and validated assay menus, high-throughput and point-of-care platforms, sequencing capabilities, and strong relationships with reference laboratories and national veterinary authorities are expected to capture the largest share of growth over the forecast period.